A late-stage medication development company specific in oncology and endocrine therapy.

Aeterna Zentaris to provide poster on AEZS-130 growth hormone secretagogue/ghrelin receptor agonist at 92nd ENDO Aeterna Zentaris Inc. , a late-stage medication development company specific in oncology and endocrine therapy, today announced a poster on its oral artificial growth hormones secretagogue/ghrelin receptor agonist, AEZS-130, will end up being presented at the upcoming 92nd Annual Endocrine Society Getting together with and Expo, june 19 through 22 which will be held, 2010 at the San Diego Convention Center in NORTH PARK, California. AEZS-130 ) is currently in a Phase 3 trial as a diagnostic check for growth hormone deficiency in adults.We believe this new model shall help develop the transformational change people are looking for in healthcare,’ said Bertolini. Zubretsky, senior executive vice CFO and president. We believe we are able to benefit both our clients and shareholders by continuing to invest to strengthen our primary business and create new growth possibilities.60 to $4.70.’ Health Care business results HEALTHCARE, which provides a complete range of covered and self-insured medical, pharmacy, dental and behavioral health services and products, reported: Operating revenue of $512.9 million for the second quarter of 2011, weighed against $467.4 million for the corresponding period in 2010 2010. The increase in operating revenue was primarily due to higher Commercial underwriting margins from improved underlying performance, partially offset by the result of lower Commercial Covered membership in 2011.